The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
Official Title: Phase II, Single-Arm Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
Study ID: NCT04622228
Brief Summary: This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with atezolizumab in participants who have extensive-stage small cell lung cancer (ES-SCLC) and are chemotherapy-navïe for their extensive-stage disease.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Cancer Hospital , Chinese Academy of Medical, Beijing City, , China
Hunan Cancer Hospital, Changsha CITY, , China
West China Hospital - Sichuan University, Chengdu City, , China
Second Affiliated Hospital of Third Military Medical University, Chongqing, , China
Fudan University Shanghai Cancer Center; Medical Oncology, Shanghai City, , China
Shanghai Pulmonary Hospital, Shanghai, , China
Tianjin Cancer Hospital, Tianjin, , China
Central South Hospital, Wuhan University, Wuhan, , China
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR